vimarsana.com

Page 60 - ஆரோக்கியம் பராமரிப்பு ஆம்ப் மருத்துவமனைகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hand To Hold® Launches Mobile App To Help NICU Parents Access Emotional Support

Hand To Hold® Launches Mobile App To Help NICU Parents Access Emotional Support Kimberly-Clark s U.S. Huggies® brand is proud to serve as the national founding sponsor as part of its HelpingHugs™ campaign to provide this support free for all parents News provided by Share this article ®, a national nonprofit organization that offers support for NICU (Neonatal Intensive Care Unit) parents, unveiled its innovative mobile app. The new app provides interactive and personalization features that allow NICU parents to connect 1:1 with Hand to Hold s team of Family Support Specialists (Mental Health Peer Support Certified NICU graduate and bereaved parents) to receive critical emotional and mental support. Thanks to Huggies

AvaSure Announces Investment from Goldman Sachs and Heritage Group

Nemysis Limited Announces Grant of First Canadian Patent for E-40

Share this article Share this article DUBLIN, May 19, 2021 /PRNewswire/  Nemysis Ltd today announced the issuance of Canada Patent Number 2,852,365 entitled Proteases able to hydrolyse gluten peptides and proteins at acid pH, from the Actinomycete Actinoallomurus . This is the first patent issued to Nemysis in Canada in the field of Celiac Disease (CeD) and management of Gluten Intolerance. The patent covers five novel Endoproteases and related sequences discovered in a soil Actinoallomurus strain and useful to produce enzymatic compositions either as a mixture or as single ingredients. The patented Endoproteases belong to the S8/S53 family of subtilisin kexin sedolisins, effective in cleaving the immunogenic epitopes of gliadin at pH between 3 and 8. The invention also includes methods for the recombinant production of the enzymatic compositions in several cell hosts. The patented enzymatic compositions are helpful for the treatment and/or prevention of Celiac Disease, derma

Sosei Heptares announces that the third novel drug candidate from its multi-target drug discovery collaboration with Pfizer has started clinical trials

Share this article Share this article TOKYO and CAMBRIDGE, England, May 19, 2021 /PRNewswire/ Sosei Group Corporation ( the Company ) (TSE: 4565) has been notified by Pfizer that the first subject in a clinical trial has been dosed with a new drug candidate nominated from the multi-target drug discovery collaboration between the two companies. Achievement of this milestone triggers a payment of US$5 million to Sosei Heptares. This candidate was nominated for advancement by Pfizer in December 2019 generating a US$3 million milestone payment at that time.   Pfizer nominated three distinct clinical candidates from the collaboration with Sosei Heptares during 2019, all of which are now progressing in Phase I clinical trials. These candidates have also now been disclosed by Pfizer as:

World Federation of Direct Selling Associations Appoints Kim Drabik of Plexus Worldwide to the Ethics Committee

World Federation of Direct Selling Associations Appoints Kim Drabik of Plexus Worldwide to the Ethics Committee Drabik will help shape consumer protection strategies News provided by Share this article SCOTTSDALE, Ariz., May 19, 2021 /PRNewswire/  Plexus Worldwide (Plexus ®), Senior Director Corporate Affairs, Kim Drabik was appointed to the Ethics Committee of the World Federation of Direct Selling Associations (WFDSA), where she will help shape the organization s efforts to develop unmatched consumer protection standards for the direct selling industry to meet the digital trends of today s consumer marketplace. Drabik has been in the direct selling industry for 30 years and will serve on the Ethics Committee until October 2023. The committee of executives will be tasked to develop unmatched consumer protection standards for the Direct Selling Industry to meet the digital trends of today s consumer marketplace. She is also currently serving on the WFDSA Governance and Fin

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.